Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands.
Drug Saf. 2012 Mar 1;35(3):221-32. doi: 10.2165/11594910-000000000-00000.
In 2010, the Netherlands Pharmacovigilance Centre Lareb received more than 4000 reports from healthcare professionals (HCPs). All HCPs received individual personal feedback containing information about the reported drug-adverse drug reaction (ADR) association. It is unclear what type of information HCPs expect in this feedback letter.
The aim of the study was to examine the expectations of the personal feedback of HCPs who reported an ADR to the Netherlands Pharmacovigilance Centre Lareb.
A questionnaire survey was conducted among a random sample of 1200 pharmacists, general practitioners (GPs) and medical specialists who reported an ADR to the Netherlands Pharmacovigilance Centre Lareb between 1 January 2009 and 27 January 2010. Responders and non-responders were compared on the basis of profession, number of reports submitted to the pharmacovigilance since 2007 and their last report being serious or not. Questions were asked about the importance of personal feedback and the type of information reporters would like to see in their personal feedback. Both linear and logistic regression analysis were performed, with correction for possible confounding factors.
The response rate to the questionnaire was 34.6% (n = 399). The type of information the respondents generally would like to see in their personal feedback is information about the time course of the ADR and information about the pharmacological mechanism. However, GPs were, in general, less interested in receiving feedback than pharmacists and medical specialists. Most of the respondents were (very) unsatisfied if they received only a confirmation letter instead of personal feedback. Personalized feedback was considered to be (very) important for reporting an ADR in the future. Most of the respondents (80.3%) stated that the personal feedback increased their knowledge. Only 0.6% of respondents had not read the personalized feedback. No differences were found between responders and non-responders, with the exception that responders had reported statistically more often to the Netherlands Pharmacovigilance Centre Lareb in the past 3 years.
Most of the respondents would like personal feedback instead of a standard confirmation letter. In general, pharmacists and medical specialists would like more information than GPs. The information in this study is useful in generating more customized personal feedback in the future, and could be useful for other pharmacovigilance centres that are interested in writing personalized feedback to make available to reporters.
2010 年，荷兰药品不良反应监测中心 Lareb 收到了来自医疗保健专业人员（HCPs）的 4000 多份报告。所有 HCPs 都收到了个人的反馈，其中包含有关报告的药物不良反应（ADR）关联的信息。目前尚不清楚 HCPs 在这种反馈信中期望哪种类型的信息。
本研究旨在检查向荷兰药品不良反应监测中心 Lareb 报告 ADR 的 HCPs 对个人反馈的期望。
对 2009 年 1 月 1 日至 2010 年 1 月 27 日期间向荷兰药品不良反应监测中心 Lareb 报告 ADR 的 1200 名药剂师、全科医生（GPs）和医学专家进行了一项问卷调查。根据专业、自 2007 年以来向药物警戒报告的数量以及最近报告的严重程度，对答复者和未答复者进行了比较。询问了个人反馈的重要性以及报告人希望在个人反馈中看到的信息类型。进行了线性和逻辑回归分析，并对可能的混杂因素进行了校正。
对问卷的回复率为 34.6%（n=399）。受访者通常希望在个人反馈中看到的信息是有关 ADR 时间过程的信息和有关药理学机制的信息。但是，与药剂师和医学专家相比，全科医生通常对接受反馈的兴趣较小。如果他们只收到确认信而不是个人反馈，大多数受访者（非常）不满意。个性化反馈被认为对未来报告 ADR 非常重要。大多数受访者（80.3%）表示，个人反馈增加了他们的知识。只有 0.6%的受访者未阅读个性化反馈。在答复者和未答复者之间未发现差异，除了答复者在过去 3 年中向荷兰药品不良反应监测中心 Lareb 报告的次数统计上更多。
大多数受访者希望获得个人反馈，而不是标准确认信。总体而言，药剂师和医学专家比全科医生希望获得更多信息。本研究中的信息可用于将来生成更具针对性的个人反馈，并且对于其他有兴趣向报告人提供个性化反馈的药物警戒中心可能会有用。
